Hypogeusia as the initial presenting symptom of COVID-19

Lauren E Melley  
*Philadelphia College of Osteopathic Medicine*

Eli Bress  
*Philadelphia College of Osteopathic Medicine*

Erik Polan  
*Philadelphia College of Osteopathic Medicine, erikpo@pcom.edu*

Follow this and additional works at: [https://digitalcommons.pcom.edu/scholarly_papers](https://digitalcommons.pcom.edu/scholarly_papers)

**Recommended Citation**  
Melley, Lauren E; Bress, Eli; and Polan, Erik, "Hypogeusia as the initial presenting symptom of COVID-19" (2020). *PCOM Scholarly Papers*. 2056.  
[https://digitalcommons.pcom.edu/scholarly_papers/2056](https://digitalcommons.pcom.edu/scholarly_papers/2056)

*This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.*
Hypogeusia as the initial presenting symptom of COVID-19

Lauren E Melley,1 Eli Bress,2 Erik Polan3

SUMMARY
COVID-19 is the disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first arose in Wuhan, China, in December 2019 and has since been declared a pandemic. The clinical sequelae vary from mild, self-limiting upper respiratory infection symptoms to severe respiratory distress, acute cardiopulmonary arrest and death. Otolaryngologists around the globe have reported a significant number of mild or otherwise asymptomatic patients with COVID-19 presenting with olfactory dysfunction. We present a case of COVID-19 resulting in intensive care unit (ICU) admission, presenting with the initial symptom of disrupted taste and flavour perception prior to respiratory involvement. After 4 days in the ICU and 6 days on the general medicine floor, our patient regained a majority of her sense of smell and was discharged with only lingering dysgeusia. In this paper, we review existing literature and the clinical course of SARS-CoV-2 in relation to the reported symptoms of hyposmia, hypogeusia and dysgeusia.

BACKGROUND
For many sick people with viral upper respiratory infections (URIs), the experience of eating food and perceiving flavour is often blunted either secondarily from rhinitis and resulting nasal obstruction or from direct viral injury to olfactory neuroepithelium. Retronasal olfaction, a combination of orthonasal smell and taste, is a sensory process that allows humans to perceive flavour, which is defined as the perception of anything beyond the five taste dimensions of food: sweet, salty, bitter, sour and umami.1 This process is temporarily impaired during URIs due to mucosal inflammation and congestion of the nasal passages, thus physically blocking the entry of odour and flavour molecules to the olfactory cleft.2 In contrast, post-URI olfactory loss is a neural process that occurs due to viral insult2 and most commonly results in hyposmia late in the course of viral infection.3 This type of viral insult can result in either temporary loss of olfaction or, in some cases, permanent loss of smell.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of many pandemic coronaviruses that have been identified. The current outbreak of COVID-19 that began in Wuhan, China, has constituted a public health emergency of international concern, now creating a global impact with over 2.4 million cases to date.4 The clinical sequelae vary from mild and self-limiting URI symptoms to severe respiratory distress, acute cardiopulmonary arrest and death.5 Coronaviruses have previously been identified as a family of viruses associated with anosmia.6 Anecdotal evidence from otorhinolaryngologists worldwide has suggested that otherwise mild cases of COVID-19 caused by the novel betacoronavirus, SARS-CoV-2, may be significantly associated with olfactory dysfunction.

We present a case of COVID-19 resulting in ICU admission, presenting with the initial symptom of disrupted taste and flavour perception prior to respiratory involvement. The purpose of this paper was to review the clinical course of SARS-CoV-2 in relation to the reported symptom of hyposmia and hypogeusia.

CASE PRESENTATION
A 59-year-old African–American female presented to our institution by ambulance on 29 March 2020, secondary to several days of shortness of breath, fatigue and loss of appetite. Medical history was significant for hypertension, hyperlipidaemia and asthma, requiring infrequent use of albuterol reported less than one time per month. Social history was notable only for a remote history of tobacco abuse, but she denied any current tobacco, drug or alcohol use. Of note, the patient did endorse that her husband, whom she lives with at home, was complaining of shortness of breath and a non-productive cough several days prior to her arrival. Her husband’s symptoms lasted only 3–4 days and had resolved completely. She reported no past otolaryngological surgeries or use of any nasal sprays, or homeopathic or herbal medications.

Roughly a week prior to admission, the patient began to experience a subtle decrease in appetite and disinterest in food. These symptoms were isolated and preceded any indication that she was ill. Over the week prior to her presentation, the foods she normally enjoys tasted ‘bland and metallic’. The patient described her diet as ‘varied and including many spices and strong flavours, particularly using herbs in Jamaican and Caribbean cuisines’. When questioned further, she also admitted to a slowly diminishing ability to smell that progressed to complete anosmia in the absence of congestion or any other nasal symptoms. However, she did not make the connection to this early symptom and the subsequent respiratory distress until specifically questioned. She noted in particular that when preparing her normal meals, she could no longer appreciate any of the typical culinary aromas.
Further, she could not smell any of her scented candles but did not think anything of it at that time. The patient denied any history of hyposmia or anosmia prior to this. It was not until a few days later when she developed a non-productive cough, malaise, shortness of breath and chest tightness that ultimately prompted her to call 911. On transit to the hospital via ambulance, the patient had an initial SpO2 of 68% on room air, and she was later placed on supplemental oxygen.

Review of symptoms was negative for any nasal obstruction, rhinorrhea, epistaxis, and nasal or head trauma. She endorsed shortness of breath, malaise and chest tightness as mentioned previously. On admission, the patient was afebrile and saturating adequately on 5 L supplemental oxygen via nasal cannula. The patient appeared fatigued and mildly distressed, and physical exam was notable for bilateral wheezes and rales, most predominant at the lung bases bilaterally. The patient had no appreciated mucosal or turbinate hypertrophy in the nasal cavity and otherwise had a normal head, eyes, ears, nose and throat examination.

INVESTIGATIONS
Laboratory values were significant for lactate dehydrogenase (410), erythrocyte sedimentation rate (42) and C reactive protein (192.1). Basic metabolic panel, liver function, renal function, myocardial enzymes and serum procalcitonin were otherwise normal. Tests for influenza A/B and *Legionella* were negative. A SARS-CoV-2 nucleic acid amplification test (NAAT) was taken by nasopharyngeal swab. A chest radiograph (see figure 1) followed by a high-resolution CT of the chest were performed, images of which reported multiple patchy ground-glass opacities in bilateral subpleural areas (see figure 2).

TREATMENT
Based on the overall clinical picture, the patient remained on contact and droplet precautions and isolation as it was assumed that she did have COVID-19. On the consult of our infectious disease physician and checking the patient’s corrected QT interval (QTc), the patient was empirically treated with the experimental therapy of hydroxychloroquine 400 mg two times per day for 1 day followed by 200 mg two times per day for 4 days, as well as azithromycin 500 mg two times per day for 1 day followed by 250 mg two times per day for 4 days.

The patient was subsequently transferred from the general floor to the ICU on the night of admission due to increased oxygen requirements with significant desaturations. The patient was initially placed on a non-rebreather and transitioned to continuous positive airway pressure (CPAP). On the advice of our pulmonologist, she remained on CPAP and intravenous steroids were initiated. The decision of early and pre-emptive intubation was discussed with our staff, but the patient did not display significant and continual signs of respiratory distress to necessitate this. While the patient was in the ICU, the result of the SARS-CoV-2 NAAT was positive for detection of the virus on 2 April 2020.

OUTCOME AND FOLLOW-UP
The patient remained in the ICU for 4 days and was subsequently downgraded to the general floor when it was felt that her respiratory status was improving, as she no longer required CPAP. On discharge on 8 April 2020, 10 days following admission, the patient endorsed that she had regained a majority of her sense of smell and that her sense of taste was greatly improved, although she did state foods did taste ‘excessively salty’ but no longer tasted metallic as noted before. She was not retested for SARS-CoV-2 prior to discharge but was advised to self-quarantine for 14 days on returning home. To limit exposure to the patient’s primary care physician, the patient was instructed to call her physician as an outpatient to review her hospitalisation. She was instructed to return to the emergency room only if she experienced severe symptoms of respiratory distress or other alarming symptoms. A timeline detailing our patient’s clinical course in relation to her gustatory and olfactory complaints is shown in figure 3.

DISCUSSION
SARS-CoV-2, a betacoronavirus, is an enveloped positive sense RNA virus that first arose in Wuhan, China, in December 2019. Officially declared a pandemic on 11 March by the WHO, COVID-19, caused by the novel coronavirus SARS-CoV-2, has affected over 2.4 million patients globally and resulted in over 169,000 deaths as of 20 April 2020.

Throughout recent weeks, reports of anosmia as a symptom of COVID-19 have flooded the media. Otolaryngologists around the globe have reported a significant number of patients with COVID-19 presenting with olfactory dysfunction, but scientific data have proven that a significant association has been

---

**Figure 1** Chest radiograph, AP, day of admission. AP, anterior–posterior; R, right.

**Figure 2** Chest CT, axial (A) and coronal (B), day of admission.
limited. A recent study in Italy using a patient questionnaire found that approximately one-third (20 of 59) of patients hospitalised with COVID-19 reported some degree of olfactory or gustatory dysfunction. Another recently accepted publication also involving olfactory and gustatory questionnaires was conducted at 12 European hospitals. Among the 417 mild-to-moderate European patients with COVID-19 involved in the Lechien et al study, 85.6% and 88.0% reported olfactory and gustatory dysfunction, respectively. The majority (65.7%) of patients reported olfactory dysfunction occurring after the appearance of general viral symptoms, however, 11.8% of patients in this study reported olfactory dysfunction appearing before any other symptoms, suggesting anosmia may be important for early COVID-19 detection. They did not assess the prevalence of gustatory dysfunctions appearing as the first symptom, similar to how our patient presented. Additionally, olfactory dysfunction was not significantly associated with rhinorrhea or nasal obstruction, hinting that the mechanism by which SARS-CoV-2 causes anosmia may be distinguishable from that of other common URI-causing viruses. However, Lechien et al did find significant associations between olfactory outcomes and several variables, including a significant association between fever and anosmia (p = 0.014). Furthermore, women were proportionally more affected by dysosmia or anosmia compared with men (p < 0.001). While more data are needed to determine if gender is a predisposing factor to the development of anosmia, the predilection for women in this study may be explained by sex dimorphisms in the olfactory bulb itself. A past study involving postmortem brains conducted in Brazil found that women have more neurons in the olfactory bulb. The higher susceptibility of women to develop olfactory and subsequent gustatory dysfunction may also be related to sex differences in inflammatory cytokine production. Future studies exploring gender and additional demographic differences in patients with COVID-19 who experience anosmia are warranted.

The study of anosmia in COVID-19 has not been limited to Europe. Using a questionnaire sent out to over 10 000 residents in all provinces of Iran, a study that is now in preprint found that there is a significant correlation between anosmia and COVID-19 in the different provinces. However, reports of anosmia in Asia have not been robust. To our knowledge, Mao et al’s study, which details the neurological manifestations of 214 patients hospitalised with COVID-19 in Wuhan, China, is one of the only studies that mention olfactory and gustatory dysfunction as symptoms associated with SARS-CoV-2. In contrast to the European studies, only 5.1% and 5.6% of patients in Mao et al’s study reported hyposmia and hypogeusia, respectively.

Earlier studies originating from the virus’ original epicentre of Wuhan have failed to mention effects on olfactory and gustatory sensation at all. This evokes many questions regarding the significance of anosmia and why it seems to be so prevalent in European populations yet hardly addressed in Asian papers. One explanation may be explained by variation in the SARS-CoV-2 genome. Analyses have revealed two major types of SARS-CoV-2, S and L, which are defined by their single-nucleotide polymorphisms. The L type was more prevalent in early stages of the outbreak in Wuhan, but its frequency has decreased. Emerging studies have also demonstrated continued evolution of SARS-CoV-2 in regard to its surface proteins, particularly the spike glycoprotein. This glycoprotein is necessary for binding cell receptors and thus determines host tropism which may explain the potential clinical differences between patients of distinct demographic areas. Another possibility is that patients with COVID-19 in the Asian population in fact did have anosmia with associated hypogeusia and dysgeusia, yet these symptoms went un-noticed or under-reported. Unlike the loss of sight, which is readily apparent to others, anosmia can be particularly insidious and go unnoticed. As in the case of our patient, she did not realise she had anosmia until her perception of flavour and ability to enjoy foods were affected. For patients who eat primarily bland foods, such as white rice, which is a staple of the Chinese diet, anosmia and its subsequent impairment on retronasal olfaction may not be evident. The need for further scientific study involving validated smell tests to determine the significance is apparent. The implications of hyposmia and the overall use of olfactory performance measures to either support or diagnose the prognosis in COVID-19 go beyond the acute disease state itself. It is well known in the literature that individuals with persistent olfactory dysfunction are at particular risk for nutritional deficiencies, development of depression and other psychiatric disorders, and the inability to detect certain ‘warning/danger’ odours like natural gas, smoke, spoiled foods and other noxious gases.
Unusual association of diseases/symptoms

This section highlights the patient’s direct quotes regarding the initial presentation of her disease, the progression that led her to the ICU and her eventual improvement and discharge from the hospital.

► ‘My husband was initially sick with what we thought was a cold. We were keeping up with the COVID-19 news and did not think that his symptoms could be it, because other than going to the grocery store, we had no direct contact with anyone. I then started to get really winded and began to cough. It was not until I spoke to the doctor at the hospital when I realized that my sense of taste and smell were off. Everything I was eating tasted off although they were recipes I made frequently. I did not know that my loss of smell was related to COVID’.

► ‘When the doctors told me I may have COVID I was very nervous and feared for my life. Everything that I heard on the news made me even more concerned about this. I had also wondered if my husband did in fact have COVID in the first place but got over it’.

► ‘I am thankful to have noticed early on to come to the hospital when I started having issues breathing as I believe my outcome would be a lot worse hadn’t I called 911’.

Patient’s perspective

► Anosmia, dysgeusia and hypogeusia appear to be early presenting symptoms of COVID-19 in select patients that may occur prior to respiratory symptoms.

► While only recently added to the Centers for Disease Control and Prevention’s list of symptoms and not yet considered stand-alone symptoms that warrant COVID-19 testing, new-onset anosmia, hypogeusia and/or dysgeusia (especially in the absence of nasal congestion) should prompt strict self-isolation to limit presumptive viral spread.

► For many, the experience of smell and its lack thereof can be particularly insidious and go relatively unnoticed without large disruption in day-to-day life.

► As clinicians, we need to be keen on these subtle and overlooked symptoms of COVID-19, especially when objective tests for anosmia are not readily available to most providers.

► Although purely anecdotal evidence for the relationship between COVID-19 infection and the symptoms of hyposmia and hypogeusia, these remain concerning symptoms and prompt further investigation.

Learning points

revisions. In addition, she served as project administrator. She, along with all three coauthors, gave final approval of the version to be published. EB contributed to project conception and writing/manuscript preparation by writing portions of the initial draft (wrote most of the case presentation and patient perspective sections.) He also contributed to critical review, commentary and revisions. All direct patient contact, history-taking and patient quotes were obtained by EB. He, along with all three coauthors, gave final approval of the version to be published. EP contributed to the project by serving as project supervisor as the attending physician taking care of the patient. His roles also included writing/manuscript preparation, specifically critical review, commentary and revisions, and final approval of the version to be published.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Unusual association of diseases/symptoms

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Lauren E Melley http://orcid.org/0000-0003-2673-8129

REFERENCES


Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

BMJ Case Report Fellows may re-use this article for personal use and teaching with any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow